[The Discovery, Research and Development of Etelcalcetide Hydrochloride, the World 1st Intravenous Calcimimetics.]
Etelcalcetide hydrochloride is the first intravenous calcimimetics agent for secondary hyperparathyroidism (SHPT). Etelcalcetide hydrochloride is to be administered through dialysis circuit by physician or medical staff upon completion of dialysis and such administration is expected to reduce the burden of medication in patients. From the nonclinical study results, etelcalcetide functions as an allosteric activator of calcium-sensing receptor(CaSR). Etelcalcetide suppressed PTH secretion both in vitro and in vivo. In a rat model of chronic renal insufficiency, etelcalcetide suppressed SHPT disorders, such as parathyroid gland hypertrophy, bone disorder, and ectopic calcification. In conclusion, etelcalcetide hydrochloride is expected to exhibit therapeutic effect against each SHPT condition by decreasing blood PTH concentrations via CaSR-agonist activity in the clinical situation.
ONO Pharmaceutical Co., Ltd, Research Headquarter, Research Promotion, Japan.
Atsuto
A
Inoue
ONO Pharmaceutical Co., Ltd, Research Headquarter, Discovery Research Laboratory, Japan.
Kazutsune
K
Harada
D000818:Animals; D057966:Calcimimetic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D002114:Calcinosis; D055808:Drug Discovery; D006801:Humans; D007275:Injections, Intravenous; D010455:Peptides / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D011379:Prognosis; D006435:Renal Dialysis
D057966:Calcimimetic Agents; D010455:Peptides; C583569:etelcalcetide hydrochloride